Factors associated with arterial vascular events in PROFILE: A multiethnic lupus cohort

Lupus

Volumn 18, Issue 11, 2009, Pages 958-965

  Bertoli, A M ^a   Vilá, Luis M ^a   Alarcon G S ^b   McGwin Jr , G ^c   Edberg, J C ^b   Petri, M ^d   Ramsey Goldman, R ^e   Reveille, J D ^f   Kimberly, R P ^b  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b University of Alabama at Birmingham   (United States)

^c Kentucky   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular disease; Systemic lupus erythematosus; Thrombosis

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGE; ANEMIA; ANGINA PECTORIS; ARTERY DISEASE; ARTHRITIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CLAUDICATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; FEMALE; GANGRENE; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEART INFARCTION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; SEIZURE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ARTERIES; CARDIOVASCULAR DISEASES; COHORT STUDIES; ETHNIC GROUPS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RISK FACTORS;

EID: 70349478695     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309104862     Document Type: Article

References (59)

1. Erkan D. Lupus and thrombosis. J Rheumatol 2006; 33: 1715-1717.
2. Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43: 924-929.
3. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-2337.
4. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-415.
5. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995; 22: 1259-1264.
6. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-2557.
7. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299-308.
8. Bjornadal L, Yin L, Granath F, Klareskog L, Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: Results from a Swedish population based study 1964-95. J Rheumatol 2004; 31: 713-719.
9. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 338-346.
10. Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: A comparison of three ethnic groups. Arthritis Rheum 2005; 52: 2774-2782.
11. Sarabi, ZS, Chang, E, Bobba, R, et al. Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthritis Rheum 2005; 53: 609-612.
12. Chang, ER, Pineau, CA, Bernatsky, S, Neville, C, Clarke, AE, Fortin, PR. Risk for incident arterial or venous vascular events varies over the course of systemic lupus erythematosus. J Rheumatol 2006; 33: 1780-1784.
13. Martinez, F, Forner, MJ, Ruano, M, Abdilla, N, Oltra, R, Garcia-Fuster, MJ. [Factors related to the risk of thrombosis in patients with lupus and antiphospholipid antibodies]. Med Clin (Barc) 2006; 127: 405-408.
14. Font, J, Cervera, R, Ramos-Casals, M, et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: Analysis of 600 patients from a single center. Semin Arthritis Rheum 2004; 33: 217-230.
15. Martinez-Berriotxoa, A, Ruiz-Irastorza, G, Egurbide, MV, Rueda, M, Aguirre, C. Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus 2004; 13: 927-933.
16. Horbach, DA. van, OE, Donders, RC, Derksen, RH, De Groot, PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-924.
17. Bizzaro, N, Ghirardello, A, Zampieri, S, et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: A 15-year longitudinal study. J Thromb Haemost 2007; 5: 1158-1164.
18. Bertolaccini, ML, Mepani, K, Sanna, G, Hughes, GR, Khamashta, MA. Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus. Ann Rheum Dis 2007; 66: 533-536.
19. Bertolaccini, ML, Mepani, K, Sanna, G, Hughes, GR, Khamashta, MA. Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus. Ann Rheum Dis 2007; 66: 533-536.
20. Booth, S, Chohan, S, Curran, JC, Karrison, T, Schmitz, A, Utset, TO. Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus. Arthritis Rheum 2007; 57: 845-850.
21. Fijnheer, R, Roest, M, Haas, FJ, De Groot, PG, Derksen, RH. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: A retrospective cohort study. J Rheumatol 1998; 25: 1737-1742.
22. Petri, M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004; 114: 593-595.
23. Petri, M, Roubenoff, R, Dallal, GE, Nadeau, MR, Selhub, J, Rosenberg, IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348(9035): 1120-1124.
24. Toloza, SM,Uribe, AG,McGwin, Jr.,G, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50: 3947-3957.
25. Alarcón, GS, McGwin, Jr., G, Petri, M, Reveille, JD, Ramsey-Goldman, R, Kimberly, RP. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 2002; 11: 95-101.
26. Tan, EM, Cohen, AS, Fries, JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
27. Hochberg, MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
28. Gladman, DD, Goldsmith, CH, Urowitz, MB, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000; 27: 373-376.
29. Alarcón, GS, McGwin, Jr., G, Petri, M, et al. Time to renal disease and end-stage renal disease in PROFILE: A multiethnic lupus cohort. PLoS Med 2006; 3: E396.
30. Szalai, AJ, Wu, J, Lange, EM, et al. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med 2005; 83: 440-447.
31. Szalai, AJ, Alarcón, GS, Calvo-Alén, J, et al. Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology (Oxford) 2005; 44: 864-868.
32. Petri, M, Spence, D, Bone, LR, Hochberg, MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: Prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992; 71: 291-302.
33. Ockene, IS, Miller, NH. Cigarette smoking, cardiovascular disease, and stroke: A statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation 1997; 96: 3243-3247.
34. American Heart Association. Smoking and cardiovascular disease. Accessed at http://www.americanheart.org/presenter.jhtml?identifier=3038016 In June 2007. 2007. Ref Type: Report.
35. Costenbader, KH, Kim, DJ, Peerzada, J, et al. Cigarette smoking and the risk of systemic lupus erythematosus: A meta-analysis. Arthritis Rheum 2004; 50: 849-857.
36. Ward, MM, Studenski, S. Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Arch Intern Med 1992; 152: 2082-2088.
37. Ghaussy, NO, Sibbitt, Jr., W, Bankhurst, AD, Qualls, CR. Cigarette smoking and disease activity in systemic lupus erythematosus.J Rheumatol 2003; 30: 1215-1221.
38. Bessant, R, Duncan, R, Ambler, G, et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Arthritis Rheum 2006; 55: 892-899.
39. Bessant, R, Duncan, R, Ambler, G, et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Arthritis Rheum 2006; 55: 892-899.
40. Calvo-Alén, J, Toloza, SM, Fernandez, M, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 2005; 52: 2060-2068.
41. Jewell,ML, McCauliffe,DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000; 42: 983-987.
42. Rahman, P, Gladman, DD, Urowitz, MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998; 25: 1716-1719.
43. Yanbaeva, DG, Dentener, MA, Creutzberg, EC, Wesseling, G, Wouters, EF. Systemic effects of smoking. Chest 2007; 131: 1557-1566.
44. Bermudez, EA, Rifai, N, Buring, JE,Manson, JE, Ridker, PM. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol 2002; 89: 1117-1119.
45. Almeida, OP, Xiao, J. Mortality associated with incident mental health disorders after stroke. Aust N Z J Psychiatry 2007; 41: 274-281.
46. Almeida, OP, Xiao, J. Mortality associated with incident mental health disorders after stroke. Aust N Z J Psychiatry 2007; 41: 274-281.
47. Sanna, G, D'Cruz, D, Cuadrado, MJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am 2006; 32: 465-490.
48. Bertoli, AM, Vilá, LM, Apte, M, et al. Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: Anaemia as a predictor of disease activity and damage accrual. Rheumatology (Oxford) 2007; 46: 1471-1476.
49. Russell, AI, Cunninghame Graham, DS, Shepherd, C, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004; 13: 137-147.
50. Zee, RY, Ridker, PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002; 162: 217-219.
51. Lange, LA, Carlson, CS, Hindorff, LA, et al. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA 2006; 296: 2703-2711.
52. Morita, A, Nakayama, T, Doba, N, Hinohara, S, Soma, M. Polymorphism of the C-reactive protein (CRP) gene is related to serum CRP level and arterial pulse wave velocity in healthy elderly Japanese. Hypertens Res 2006; 29: 323-331.
53. Crawford, DC, Sanders, CL, Qin, X, et al. Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation 2006; 114: 2458-2465.
54. Mok, MY, Chan, EY, Fong, DY, Leung, KF, Wong, WS, Lau, CS. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J Rheumatol 2005; 32: 622-628.
55. Tarr, T, Lakos, G, Bhattoa, HP, Shoenfeld, Y, Szegedi, G, Kiss, E. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 2007; 16: 39-45.
56. Henderson, SO, Haiman, CA, Wilkens, LR, Kolonel, LN, Wan, P, Pike, MC. Established risk factors account for most of the racial differences in cardiovascular disease mortality. PLoS ONE 2007; 2: E377.
57. Kronmal, RA, McClelland, RL, Detrano, R, et al. Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2007; 115: 2722-2730.
58. Muñoz-Rodrøguez, FJ, Reverter, JC, Font, J, et al. Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. Haematologica 2000; 85: 632-637.
59. Brouwer, JL, Bijl, M, Veeger, NJ, Kluin-Nelemans, HC. van der Meer, J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004; 104: 143-148.